Etomoxir (Standard)

Etomoxir (Standard) is the analytical standard of Etomoxir. This product is intended for research and analytical applications. Etomoxir ((R) - (+) -Etomoxir) is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.

Product Specifications

CAS Number

[124083-20-1]

UNSPSC

12352100

Target

Apoptosis; Reference Standards

Related Pathways

Apoptosis; Others

Field of Research

Cancer; Metabolic Disease

Smiles

O=C(OCC)[C@@]1(OC1)CCCCCCOC2=CC=C(C=C2)Cl

Molecular Formula

C17H23ClO4

Molecular Weight

326.82

References & Citations

[1]Rupp H, et al. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz. 2002 Nov;27 (7) :621-36.|[2]Xu FY, et al. Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells. J Lipid Res. 2003 Feb;44 (2) :415-23.|[3]Li J, et al. FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus. Sci Rep. 2015 Jul 31;5:12724.|[4]Luiken JJ, et al. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates. Biochem J. 2009 Apr 15;419 (2) :447-55.|[5]O'Connor RS, et al. The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. Sci Rep. 2018 Apr 19;8 (1) :6289.